Currently, a phase 1 clinical trial is carried out in patients with advanced KRAS-mutated cancers (NCT03948763).23 Wilms’ tumor 1 (WT1) is an immunogenic antigen which is overexpressed in acute myeloid leukemia. Here, KRAS is linked to cancer.